US industry buoyed by Congress moves
This article was originally published in Clinica
US medical device makers are riding a fairly high wave in Congress at present, with Congress poised to finalise in a matter of weeks a bill that would solidify a five-year agreement allowing the Food and Drug Administration to collect user fees from the device industry in exchange for faster and more predictable product reviews. In addition, federal legislators are considering a substantial increase in the FDA's budget, including increases for review of medical devices.
You may also be interested in...
GNC announces "significant" store and management staff furloughs and other cost-cutting moves "to protect the long-term prospects for the business." Vitamin Shoppe told customers that its stores remain open though it reduced business hours.
California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.
Following the US request for ranitidine drugs to be withdrawn from the market, the European Medicines Agency says it would decide the fate of the products in the EU after wrapping up its own inquiry.